Polyepitopic fragments (I) from the human p53 that is overexpressed in many types of cancers, are new. Polyepitopic fragments (I) from the human p53 that is overexpressed in many types of cancers, are new. (I) is contained within any of the sequences ThrTyrGlnGlySerTyrGlyPheArgLeuGlyPheLeuHisSerGlyThrAlaLysSerVal- ThrCysThrTyrSerProAlaLeuAsnLysMetPheCysGlnLeu； SerThrProProProGlyThrArgValArgAlaMetAlaIleTyrLysGlnSerGlnHisMet； GlyLeuAlaProProGlnHisLeuIleArgValGluGlyAsnLeuArgValGluTyrLeuAsp- AspArgAsnThrPheArgHisSerValValValProTyr； GlySerAspCysThrThrIleHisTyrAsnTyrMetCysAsnSerSerCysMet； ArgProIleLeuThrIleIleThrLeuGluAspSerSerGlyAsnLeuLeuGlyArgAsnSer- PheGluValArg. These represent, respectively, amino acids 102-137, 149-169, 187-212, 226-243 or 249-273 of p53, and bind stably to, respectively, the human leukocyte antigen (HLA) type molecules A2, A24 or B62； A2, A3, A24, B27, B35, or B62； A2, A24, B27 or B44； A1, A24 or B44； or A2, B27, B35, B44 or B62. Alternatively, (I) may be a derivative of the sequences, binding to the same HLA molecules as the parent compounds, formed by substitution, deletion and/or addition of one or more amino acids, modification of at least one peptide bond (particularly replacement by retro or retro-inverso bonds) and/or substitution of at least one amino acid by a non-proteinogenic amino acid. Independent claims are also included for the following: (1) nucleic acid (II) that encodes (I) or its derivatives； (2) mono- or poly-clonal antibodies (Ab) directed against (I) or its derivatives； and (3) pharmaceutical composition or vaccine containing at least one (I), or its derivative, (II) or Ab. - ACTIVITY : Cytostatic. No biological data is given. - MECHANISM OF ACTION : (I) induces a specific immune response； they induce cytolysis, by cytotoxic T cells (CTL), of cells that express (I) associated with appropriate HLA molecules and induce secretion of cytokines (particularly interleukins -2 and -4, and gamma -interferon) by these CTL； vaccine
